1.Expression of EGFR about different region tissues and its relationship with histological differentiation in laryngeal carcinoma.
Shiwen ZHANG ; Xiaoguang HE ; Xiaojiang LI ; Yuanling WANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2012;26(3):123-128
OBJECTIVE:
To detect the expression of EGFR in different region of laryngeal tissue, and use quantitive analysis to discuss the relation between expression of EGFR and histological differentiation.
METHOD:
Collected 36 cases of laryngeal tissue example, which be divided in to three groups based on pathobiology. Using Western Blot to detect the EGFR expression in cancer tissue, para cancer tissue and normal tissue, and combined imaging analytical technique to analyse the relation between expression of EGFR and histological differentiation.
RESULT:
In same region of cancer tissue the expression of EGFR is different along with different tissue differentiation (P<0.05), but in normal tissue this different is not existing (P>0.05). In same tissue differentiation the expression of EGFR is different in cancer tissue, para cancer tissue and normal tissue (P<0.05).
CONCLUSION
EGFR highly express in laryngeal cancer tissue, and relate with the tissue differentiation of laryngeal cancer. EGFR is an important indicator to study the emerging and progression of laryngeal cancer.
Carcinoma, Squamous Cell
;
metabolism
;
pathology
;
Cell Differentiation
;
ErbB Receptors
;
metabolism
;
Humans
;
Laryngeal Neoplasms
;
metabolism
;
pathology
2.Expression and clinical significance of MICA in laryngeal carcinoma tissue and cells.
Rui WANG ; Junfu WANG ; Qinghong SU ; Xuemei CHEN ; Xiaoqun XU
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2016;30(2):94-97
OBJECTIVE:
To investigate the mRNA and protein expression of MICA in laryngeal squamous cell carcinoma tissue and the Hep-2 cells.
METHOD:
Reverse transcriptase-polymerase chain reaction (RT-PCR) and Western-blot were used to detect the expression of MICA mRNA and protein levels in the Hep-2 cells and laryngeal cancer tissues.
RESULT:
The MICA mRNA showed higher expression in Hep-2 cells by RT-PCR. Compared with the control, the mRNA expression of MICA was significantly enhanced in laryngeal cancer tissues (t = 11.878, P < 0.01). The intensity of MICA expression is not related to the clinical stage of cancer. MICA protein demonstrated higher level expression by Western blot. The intensity of MICA protein expression was decreased with increased clinical stage in laryngeal cancer tissues.
CONCLUSION
The MICA mRNA showed stronger expression in Hep-2 cells and laryngeal cancer tissues. The intensity of its expression is not related to clinical stage of cancer. The MICA protein expression was strong in Hep-2 cells. The intensity of MICA protein expression was decreased with increased clinical stage in laryngeal cancer tissues. MICA may play an important role in laryngeal carcinoma process.
Carcinoma, Squamous Cell
;
metabolism
;
pathology
;
Cell Line, Tumor
;
Head and Neck Neoplasms
;
metabolism
;
pathology
;
Histocompatibility Antigens Class I
;
metabolism
;
Humans
;
Laryngeal Neoplasms
;
metabolism
;
pathology
;
Squamous Cell Carcinoma of Head and Neck
3.Research progress of prognostic protein biomarkers associated with esophagus squamous cell carcinoma.
Hui LI ; Lu-yan SHEN ; Ke-neng CHEN
Chinese Journal of Gastrointestinal Surgery 2012;15(9):984-988
Esophageal cancer (EC) is one of the common malignant tumors in China. Esophagectomy based on multi-disciplinary principle improves the quality of life and survival of esophageal cancer patients, but a lot of patients will suffer recurrence or metastasis after surgery. TNM stage is the most important factor which affects the prognosis of patients with esophageal cancer. Besides, there are other prognostic factors, such as abnormal expression of the proteins. Exploration of these proteins may provide new clues to improve prognosis in esophageal squamous cell cancer (ESCC). We reviewed the literatures related to abnormal protein expression in ESCC, and tried to elucidate the prognostic value and potential clinical application of these proteins in ESCC.
Biomarkers, Tumor
;
metabolism
;
Carcinoma, Squamous Cell
;
metabolism
;
Esophageal Neoplasms
;
metabolism
;
Humans
;
Prognosis
;
Proteins
;
metabolism
4.MicroRNA in head and neck carcinoma.
Chinese Journal of Pathology 2013;42(5):355-358
5.Study on the relationship between Fas expression and apoptosis in oral squamous cell carcinoma.
Jian-guang WANG ; Hong-zhang HUANG ; Chao-bin PAN ; Jin-song HOU ; Jin-song LI ; Bin CHENG
West China Journal of Stomatology 2004;22(4):334-336
OBJECTIVETo investigate the relationship of Fas mRNA and protein expression and apoptosis in human oral squamous cell carcinoma.
METHODSNorthern blot and flow cytometry (TUNEL method) were used to detect the expression of Fas mRNA and Fas protein, cell cycle and apoptotic level in oral squamous cell carcinoma. The relationship between Fas gene expression and OSCC apoptosis was analyzed statistically.
RESULTSFas mRNA and protein could be detected in all five normal oral mucosa specimens. There was positive correlation between expression of Fas mRNA/protein and cell differentiation as well as apoptosis in OSCC (P < 0.005).
CONCLUSIONThe expression of Fas gene was highly correlated with the differentiation and apoptosis in OSCC.
Apoptosis ; Carcinoma, Squamous Cell ; metabolism ; Humans ; Mouth Neoplasms ; metabolism ; fas Receptor ; metabolism
7.Clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma of the breast.
Bei Bei GAO ; Qin ZHENG ; Lan YU ; Dan Ju LUO ; Xiu NIE ; Xia XU
Chinese Journal of Pathology 2022;51(9):843-849
Objective: To investigate the clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma (MSCC) of the breast. Methods: A total of 47 MSCC cases diagnosed in the Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China from January 2010 to December 2021 were reviewed. The clinical information (including the follow-up data of HER2 positive patients) and pathological features were collected and analyzed. Results: All of the patients were female. Among the 47 cases, 25 were pure squamous cell carcinoma (PSCC) and 22 were mixed metaplastic carcinoma with squamous cell component (MMSC). The median age of the patients was 54 years (range, 29-84 years). The maximum diameter of the mass ranged from 0.8 to 10.0 cm, with a mean value of 3.3 cm, 85.7% (24/28) of the cases were smaller than 5 cm, and only 4 cases were larger than or equal to 5 cm. 89.5% of the MMSC presented with a solid mass. Cystic changes were more commonly found in the PSCC group (50%, P<0.05) than the MMSC group. 36.7% (11/30) of the patients had lymph node metastasis at the time of diagnosis. The squamous cell carcinoma component in all cases showed diffuse or patchy expression of p63, p40 and CK5/6. 55.3% (26/47) of the cases showed triple-negative phenotype. Among the 7 HER2-positive patients, 6 were MMSC group, which had a significantly higher rate of HER2-positivity than that in the PSCC group (1 case). In 1 MMSC case, immunohistochemistry showed HER2 2+in the invasive ductal carcinoma component and HER2 negativity (0) in the squamous cell carcinoma component, but HER2 FISH was negative in invasive ductal carcinoma and positive in squamous cell carcinoma component. Six HER2-positive MSCC patients received anti-HER2-targeted therapy, including two patients who received neoadjuvant chemotherapy combined with anti-HER2-targeted therapy before surgery. One patient achieved pathological complete remission, while the other achieved partial remission (the residual tumors were squamous cell carcinoma components). After 9-26 months of follow-up, four patients had no disease progression, two patients developed pulmonary metastases, and one patient showed local recurrence. Conclusions: MSCC is a group of heterogeneous diseases. PSCC and MMSC may be two different entities. Most of the MSCC are triple-negative and HER2 positivity is more commonly seen in MMSC with invasive ductal carcinoma component. Some HER2-positive MSCC patients can achieve complete remission or long-term progression-free survival after receiving anti-HER2 targeted therapy, but the squamous cell carcinoma component may be less sensitive to targeted therapy than the invasive ductal carcinoma component.
Carcinoma, Ductal
;
Carcinoma, Squamous Cell/pathology*
;
Female
;
Humans
;
Immunohistochemistry
;
Lymphatic Metastasis
;
Male
;
Receptor, ErbB-2/metabolism*
8.Expression of CD40 and Fas Ligand in Bowen's Disease, Squamous Cell Carcinoma and Basal Cell Carcinoma.
Yonsei Medical Journal 2002;43(3):304-308
Impaired regulation of apoptosis is known to be associated with the development of various cancers, and Fas/Fas-ligand (FasL) is known to play an important role in apoptosis. CD40 is a cell surface receptor, which when ligated modulates apoptosis in some cell types. The expressions of CD40 and FasL were examined in 10 normal skins, 7 Bowen's disease skins, 10 squamous cell carcinomas (SCCs) and 12 basal cell carcinomas (BCCs) immunohistochemically. In the normal epidermis, CD40 was more highly expressed in the keratinocytes of the squamous cell and granular layers than in those of the basal layer, and FasL expression was observed in the cell membrane of keratinocytes at the basal and squamous cell layers. CD40 expression was significantly higher in SCCs than in normal or Bowen's disease skin, while FasL expression was significantly higher in Bowen's disease than in SCCs. BCCs expressed the lowest levels of CD40 and FasL. These results suggest that altered CD40 and FasL expression may be related with the progression of SCC, and the marked reduced expression of CD40 and FasL may explain the biologic behavior of BCCs.
Antigens, CD40/*metabolism
;
Bowen's Disease/*metabolism
;
Carcinoma, Basal Cell/*metabolism
;
Carcinoma, Squamous Cell/*metabolism
;
Human
;
Membrane Glycoproteins/*metabolism
;
Reference Values
;
Skin/metabolism
;
Skin Neoplasms/*metabolism
9.m6A modification of mRNA in skin diseases.
Journal of Central South University(Medical Sciences) 2022;47(8):1154-1162
N6-methyladenosine (m6A) is the predominant post-transcriptional modification for eukaryotic mRNA. It's regulated by methyltransferases, demethylases, and m6A binding proteins, and plays an important role in regulating splicing, translation, and degradation of mRNA. Skin diseases, especially immune skin diseases and skin tumors, have a complicated pathogenesis and are refractory to treatment, seriously affecting the patient quality of life. Recent studies have revealed that m6A and its regulatory proteins can affect the development of numerous skin diseases. The m6A modification was found to be involved in skin accessory development, including hair follicle and sweat gland formation. The level of m6A modification was significantly altered in a variety of skin diseases including melanoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and psoriasis, and affected a variety of biological processes including cell proliferation and differentiation migration. The m6A and its regulatory proteins may become potential molecular markers or therapeutic targets for skin diseases, and have promising clinical applications in early diagnosis, efficacy determination, prognosis prediction, and gene therapy of skin diseases.
Adenosine/metabolism*
;
Carcinoma, Squamous Cell
;
Humans
;
Quality of Life
;
RNA, Messenger/metabolism*
;
Skin Neoplasms/genetics*
10.Effect of PAIP1 on the metastatic potential and prognostic significance in oral squamous cell carcinoma.
Neeti SWARUP ; Kyoung-Ok HONG ; Kunal CHAWLA ; Su-Jung CHOI ; Ji-Ae SHIN ; Kyu-Young OH ; Hye-Jung YOON ; Jae-Il LEE ; Sung-Dae CHO ; Seong-Doo HONG
International Journal of Oral Science 2022;14(1):9-9
Poly Adenylate Binding Protein Interacting protein 1 (PAIP1) plays a critical role in translation initiation and is associated with the several cancer types. However, its function and clinical significance have not yet been described in oral squamous cell carcinoma (OSCC) and its associated features like lymph node metastasis (LNM). Here, we used the data available from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) to analyze PAIP1 expression in oral cancer. The publicly available data suggests that PAIP1 mRNA and protein levels were increased in OSCC. The high PAIP1 expression was more evident in samples with advanced stage, LNM, and worse pattern of invasion. Moreover, the in vitro experiments revealed that PAIP1 knockdown attenuated colony forming, the aggressiveness of OSCC cell lines, decreasing MMP9 activity and SRC phosphorylation. Importantly, we found a correlation between PAIP1 and pSRC through the analysis of the IHC scores and CPTAC data in patient samples. Our findings suggest that PAIP1 could be an independent prognostic factor in OSCC with LNM and a suitable therapeutic target to improve OSCC patient outcomes.
Carcinoma, Squamous Cell/genetics*
;
Head and Neck Neoplasms
;
Humans
;
Lymphatic Metastasis
;
Mouth Neoplasms/pathology*
;
Peptide Initiation Factors/metabolism*
;
Prognosis
;
Proteomics
;
RNA-Binding Proteins/metabolism*
;
Squamous Cell Carcinoma of Head and Neck